BI 1015550 NEW
| Price | $59 | $127 | $197 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-15 |
Product Details
| Product Name: BI 1015550 | CAS No.: 1423719-30-5 |
| Purity: 99.71% | Supply Ability: 10g |
| Release date: 2025/07/15 |
Product Introduction
Bioactivity
| Name | BI 1015550 |
| Description | Nerandomilast (BI 1015550) is an orally active PDE4B inhibitor with IC50 of 7.2 nM. BI 1015550 has potential applications in inflammation, allergic diseases, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) with a good safety profile. |
| In vitro | METHODS: Rats were treated with Nerandomilast (BI 1015550) (0.0001-100mM) to study its effect on LPS-stimulated TNF-α release in rat whole blood. RESULTS BI 1015550 completely inhibited TNF-α release in rat whole blood with an IC50 value of 91 nM; high concentrations of BI 1015550 resulted in a concentration-dependent four-fold increase in IL-6 in rats. [1] |
| In vivo | METHODS: Rats were treated with Nerandomilast (BI 1015550) (0.01, 0.1, 1, 3 mg/kg, oral) to study its effect on LPS-stimulated TNF-α release in rat whole blood. RESULTS BI 1015550 at a dose of 3 mg/kg inhibited 93% of TNF-α release. The final experimental result showed that the dose of BI 1015550 that caused half-maximal inhibition (ED50) of LPS-induced TNF-α release was 0.04 mg/kg. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 4.49 mg/mL (10 mM), Sonication is recommended. |
| Keywords | PDE4B | BI-1015550 | BI1015550 | BI 1015550 |
| Inhibitors Related | Theophylline monohydrate | Acefylline | Roflumilast | Theobromine | Apremilast | Isoprenaline hydrochloride | Indomethacin | Icariin | Theophylline | Vardenafil hydrochloride | Doxofylline | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Anti-Fibrosis Compound Library | Metabolism Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/100MG |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-19 | |
| $40.00/1kg |
VIP6Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-10-10 | |
| $0.00/1kg |
VIP1Y
|
Wuhan Circle Star Chem-medical Technology Co.,Ltd
|
2025-01-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY